Appili Therapeutics Inc.
APLI.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 144.72% | 66.70% | -60.38% | -88.23% | -88.23% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 144.72% | 66.70% | -60.38% | -88.23% | -88.23% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 144.72% | 66.70% | -60.38% | -88.23% | -88.23% |
| SG&A Expenses | -13.35% | -11.41% | -10.72% | -12.29% | -15.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.55% | -38.55% | -27.68% | -7.24% | 11.35% |
| Operating Income | 35.32% | 39.84% | 26.03% | -0.57% | -21.55% |
| Income Before Tax | -55.95% | 28.55% | 32.22% | 41.29% | 30.92% |
| Income Tax Expenses | 542.75% | 18,400.00% | 399.17% | -16.51% | -74.66% |
| Earnings from Continuing Operations | -59.28% | 26.00% | 30.26% | 40.93% | 31.74% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -59.28% | 26.00% | 30.26% | 40.93% | 31.74% |
| EBIT | 35.32% | 39.84% | 26.03% | -0.57% | -21.55% |
| EBITDA | 35.34% | 39.88% | 26.07% | -0.57% | -21.60% |
| EPS Basic | -60.38% | 27.62% | 30.41% | 40.95% | 31.17% |
| Normalized Basic EPS | -56.57% | 30.00% | 32.35% | 41.67% | 30.77% |
| EPS Diluted | -60.38% | 27.62% | 30.41% | 40.95% | 31.17% |
| Normalized Diluted EPS | -56.57% | 30.00% | 32.35% | 41.67% | 30.77% |
| Average Basic Shares Outstanding | -0.90% | 1.46% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | -0.90% | 1.46% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |